Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | AGXT | P21549 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071390 | 0.85 | CTBP2 (0.64) | CTBP2ALDH1A1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL15513856 | 0.84 | CTBP2 (0.62) | CTBP2ALDH1A1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL269177 | 0.84 | CTBP2 (0.62) | CTBP2ALDH1A1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL229067 | 0.84 | PTGS1 (0.67) | CTBP2ALDH1A1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL7898755 | 0.84 | FAAH (0.46) | CTBP2ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL29824310 | 0.84 | PTGS1 (0.67) | CTBP2ALDH1A1HTTSMN1; SMN2CYP1A2 | |
| SCHEMBL7956017 | 0.83 | P2RX3 (0.48) | CTBP2ALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL3257076 | 0.83 | HDAC1 (0.57) | ALDH1A1HTTSMN1; SMN2TAAR1MTNR1A | |
| SCHEMBL5394435 | 0.83 | CYP3A4 (0.54) | CTBP2ALDH1A1MEN1KMT2A | |
| SCHEMBL3005839 | 0.83 | ALDH1A1 (0.61) | CTBP2ALDH1A1HTTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 755 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510429-A | Compound containing methyl isoxazole structure, and preparation method and application thereof | 中国农业大学 | 2024-02-06 | — | — | CN | claimed |
| CN-113233964-A | Synthesis method of 5-methoxy-2-tetralone | 武汉工程大学 | 2021-08-10 | — | — | CN | claimed |
| CN-107011227-B | Nitrine based on tubulin-beta-lactam Small-molecule probe and its preparation method and application | 郑州大学 | 2019-08-09 | — | — | CN | claimed |
| CN-107011227-A | Nitrine beta-lactam Small-molecule probe based on tubulin and its preparation method and application | 郑州大学 | 2017-08-04 | — | — | CN | claimed |
| EP-1506176-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2013-04-24 | — | — | EP | claimed |
| EP-1556417-B1 | RACEMOSELECTIVE PREPARATION OF BRIDGED METALLOCENE COMPLEXES HAVING UNSUBSTITUTED OR 2-SUBSTITUTED INDENYL LIGANDS | BASELL POLYOLEFINE GMBH (DE) | 2009-06-10 | — | — | EP | claimed |
| US-7358381-B2 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | BASELL POLYOLEFINE GMBH (DE) | 2008-04-15 | — | — | US | claimed |
| CN-1271057-C | Method for preparing 1-methyl-3-ethyl-3-(3-hydroxy phenyl)-hexa hydrogen-1 H azepin hydrochloride | UNIV FUDAN (CN) | 2006-08-23 | — | — | CN | claimed |
| EP-1554297-B1 | RACEMOSELECTIVE SYNTHESIS OF RAC-DIORGANOSILYLBIS(2-METHYLBENZO¬E|INDEYL) ZIRCONIUM COMPONDS | BASELL POLYOLEFINE GMBH (DE) | 2006-07-12 | — | — | EP | claimed |
| US-20060111527-A1 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | EQUISTAR CHEMICALS, LP | 2006-05-25 | — | — | US | claimed |
| EP-1556417-A2 | RACEMOSELECTIVE PREPARATION OF BRIDGED METALLOCENE COMPLEXES HAVING UNSUBSTITUTED OR 2-SUBSTITUTED INDENYL LIGANDS | Basell Polyolefine GmbH (DE) | 2005-07-27 | — | — | EP | claimed |
| EP-1554297-A1 | RACEMOSELECTIVE SYNTHESIS OF RAC-DIORGANOSILYLBIS(2-METHYLBENZO[E]INDEYL) ZIRCONIUM COMPONDS | Basell Polyolefine GmbH (DE) | 2005-07-20 | — | — | EP | claimed |
| WO-2004037834-A2 | RACEMOSELECTIVE PREPARATION OF BRIDGED METALLOCENE COMPLEXES HAVING UNSUBSTITUTED OR 2-SUBSTITUTED INDENYL LIGANDS | BASELL POLYOLEFINE GMBH (DE) | 2004-05-06 | — | — | WO | claimed |
| WO-2004037840-A1 | RACEMOSELECTIVE SYNTHESIS OF RAC-DIORGANOSILYLBIS(2-METHYLBENZO[E]INDEYL) ZIRCONIUM COMPONDS | BASELL POLYOLEFINE GMBH (DE) | 2004-05-06 | — | — | WO | claimed |
| EP-4731630-A1 | HOMOPHTHALAZINONE INDOLE PARP INHIBITORS AND METHODS OF USE | Valo Health, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| US-3994888-A | Cephalosporin cleavage process | ELI LILLY AND COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
| US-3965093-A | 6-Arylthio penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3954744-A | ANTIBACTERIAL | E. R. SQUIBB & SONS, INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | CTBP2 3331/4885ALDH1A1 2229/4885HTT 3843/4885 |
| US-20060111527-A1 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | ITPA, IMPA1, INTS9 | CTBP2 1074/4885ALDH1A1 888/4885HTT 4513/4885 |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | RIPK1, RIPK3, RIPK4 | CTBP2 2846/4885ALDH1A1 4164/4885HTT 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.